EXTON, Pa., June 13, 2018 /PRNewswire/ -- (Booth
#1933) -- West Pharmaceutical Services, Inc. (NYSE: WST), a
global leader in innovative solutions for injectable drug
administration, today announced that it has received the Silver
Medical Design Excellence Award for "Drug-Delivery and Combination
Products" for its SelfDose™ Patient-Controlled Injector. The honor
was presented to West and its customer Accord Healthcare Limited,
which uses the SelfDose patient-controlled injector technology with
its Methofill™ (methotrexate) SELF INJECT, on June 12, 2018 at the MD&M East Conference in
New York City.
Organized by Medical Device and Diagnostic Industry
magazine, the annual Medical Design Excellence Awards (MDEA)
competition recognizes significant achievements in medical product
design and engineering and the many people behind the
scenes—engineers, scientists, designers and clinicians—who are
responsible for the cutting-edge products that are improving
patient healthcare. Winners are selected by a jury of healthcare
practitioners, designers, engineers, manufacturers and human
factors experts.
"The MDEA is the medtech industry's premier design
competition, and we are honored to receive this recognition for our
SelfDose patient-controlled injector," said Erin O'Brien, Vice President, Product Management
& Marketing Operations, West. "As a trusted partner
to the world's top pharmaceutical and biotechnology
companies, we understand the important role our products have in
delivering medications to patients safely and effectively. This
award underscores both our focus on quality and innovation and our
commitment to helping customers across the globe improve patient
outcomes."
The SelfDose patient-controlled injector is ergonomically
designed for optimal patient administration.
Patient-centric features include a simple, two-step operation to
deliver a subcutaneous injection, as well as audible and visual
end-of-dose indicators to confirm successful administration of a
prescribed dose. Additionally, a passive safety system covers the
needle before and after injection to help prevent needlestick
injuries to the patient and caregiver. Extensive human factors
studies have been performed with the SelfDose injector, confirming
the intuitive design and supporting its ease of use and patient
acceptance.
In addition to the SelfDose patient-controlled injector,
at MD&M East West is highlighting plans for
expanded capabilities at its Tempe,
Arizona, and Dublin,
Ireland contract manufacturing sites to meet growing demand
for sensitive drug handling and cold storage solutions and
innovative, patient-centric drug delivery system
development. The new capabilities include
electronics integration, drug and reagent packaging and product
serialization to provide comprehensive support to pharmaceutical
partners from concept through commercialization.
For more information on West products and services please
visit booth #1933 at MD&M East or visit us online at
www.westpharma.com.
Forward-Looking Statements
Certain
forward-looking statements are included in this release. These
statements reflect management's current expectations regarding
future events and operating performance and speak only as of the
date of this release. There is no certainty that West's
SelfDose patient-controlled injector, or any
other products, will achieve any level of commercial success. These
forward-looking statements involve a number of risks and
uncertainties. For a description of certain additional factors that
could cause West's future results to differ from those expressed in
any such forward-looking statements, see Item 1A, entitled "Risk
Factors," in West's Annual Report on Form 10-K for the year ended
December 31, 2017. Except as required
by law or regulation, we undertake no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
About West
West Pharmaceutical
Services, Inc. is a leading manufacturer of packaging components
and delivery systems for injectable drugs and healthcare products.
Working by the side of its customers from concept to patient, West
creates products that promote the efficiency, reliability and
safety of the world's pharmaceutical drug supply. West is
headquartered in Exton,
Pennsylvania, and supports its customers from locations in
North and South America,
Europe, Asia and Australia. West's 2017 net sales of
$1.6 billion reflect the daily use of
approximately 112 million of its components and devices, which are
designed to improve the delivery of healthcare to patients around
the world.
West and the diamond logo, By your side for a healthier
world™ and
SelfDose™ are registered
trademarks or trademarks of West Pharmaceutical Services, Inc., in
the United States and other
jurisdictions.
Methofill™ is a
registered trademark of Accord Healthcare Limited in the European
Union and is used with permission.
Media Contact:
Michele Pelkowski
Global Communications
West Pharmaceutical Services, Inc.
+ 1-610-594-3054
Michele.Pelkowski@westpharma.com
View original
content:http://www.prnewswire.com/news-releases/wests-selfdose-patient-controlled-injector-wins-silver-medical-design-excellence-award-300665789.html
SOURCE West Pharmaceutical Services, Inc.